DelveInsight’s “Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Glioblastoma Multiforme market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Glioblastoma Multiforme drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Glioblastoma Multiforme treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Glioblastoma Multiforme: An Overview
Glioblastoma Multiforme (GBM) is the most frequently occurring type of primary tumor of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that innovative diagnostic strategies and new therapies have been developed.
GBM is the most common and aggressive type of primary brain tumor in humans, accounting for 52% of all primary brain tumor cases and 20% of all intracranial tumors. GBM can present with focal or generalized signs due to mass effect, parenchymal infiltration, and destruction. Neurological symptoms of GBM include a headache that tends to worsen in the morning, vomiting, nausea, seizures, cognitive dysfunction, speech problems (difficulty in finding the right words), vision problems (abnormal eye movement), etc.
GBMs can be classified into primary and secondary GBMs. Primary GBM occurs de novo without evidence of a less malignant precursor, while Secondary GBM develops from initially low-grade diffuse astrocytoma (WHO grade II diffuse astrocytoma) or anaplastic astrocytoma (Grade III).
Glioblastoma Multiforme Market Key Facts
-
The United States accounts for the largest market size of Glioblastoma Multiforme throughout the study period of 2018-2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 674 Million in 2020.
-
Among the EU5 countries, Germany had the highest market size with USD 72.1 Million in 2020, while Spain had the lowest market size with USD 35.8 Million.
-
The market size of Japan was estimated to be USD 52.6 Million in 2020.
-
The total diagnosed incident population of Glioblastoma Multiforme in the 7 major markets was estimated to be 29,440 in 2020. In the case of Glioblastoma Multiforme patients in the United States, the diagnosed incident cases were 15,426 in 2020.
-
The total diagnosed incident cases of Glioblastoma Multiforme patients were maximum in males as compared to females in the 7 MM during the study period of 2018–2030.
-
In the EU5 countries, the diagnosed incident population of Glioblastoma Multiforme was maximum in Germany with 2,945 cases followed by France with 2,772 cases in 2020. While Spain accounted for the lowest diagnosed incident population of 1,462 in 2020.
-
As per Delvelnsight’s analysis, Japan had 1,950 diagnosed incident cases of Glioblastoma Multiforme in 2020.
Glioblastoma Multiforme Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Glioblastoma Multiforme pipeline therapies. It also thoroughly assesses the Glioblastoma Multiforme market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Glioblastoma Multiforme drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Glioblastoma Multiforme Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Glioblastoma Multiforme epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Glioblastoma Multiforme epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Glioblastoma Multiforme Epidemiology, Segmented as –
-
Total Incident Cases of GBM in the 7MM [2019-2032]
-
Gender-specific Incident Cases of GBM in the 7MM [2019-2032]
-
Incident Cases based on the Primary Site of GBM in the 7MM [2019-2032]
-
Age-specific Incident Cases of GBM in the 7MM [2019-2032]
-
Type-specific Incident Cases of GBM in the 7MM [2019-2032]
-
Incident Cases Based on Histologic Classification of GBM in the 7MM [2019-2032]
Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Glioblastoma Multiforme market or expected to be launched during the study period. The analysis covers the Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Glioblastoma Multiforme drugs based on their sale and market share.
The report also covers the Glioblastoma Multiforme pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Glioblastoma Multiforme companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Glioblastoma Multiforme Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
Glioblastoma Multiforme Therapeutics Analysis
The first-line treatment of GBM involves drug therapy following surgery, which includes Temozolomide + Radiation Therapy and Temozolomide Monotherapy. While the second-line treatment for GBM includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant).
The dynamics of the GBM market are anticipated to change in the coming years owing to the improvement in the research and development activities so that the market will comprise efficient treatment options. The launch of emerging therapies is expected during the forecast period.
Glioblastoma Multiforme Companies Actively Working in the Therapeutics Market Include
-
Genentech
-
Merck
-
Daiichi Sankyo
-
VBL Therapeutics
-
Diffusion Pharmaceuticals Bayer
-
MedImmune
-
DNAtrix
-
Chimerix
-
Karyopharm Therapeutics
-
VBI Vaccines
-
Kazia Therapeutics
-
Aivita Biomedical
-
Medicenna Therapeutics
-
Kintara Therapeutics
-
Laminar Pharmaceuticals
-
Immunomic Therapeutics
-
Inovio Pharmaceuticals
-
Treovir
-
Istari Oncology
-
Frequently
And Many Others
Emerging and Marketed Glioblastoma Multiforme Therapies Covered in the Report Include:
-
Ofranergene obadenovec (VB-111): VBL Therapeutics
-
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
-
Regorafenib: Bayer
-
Durvalumab (MEDI4736): MedImmune
-
Tasadenoturev (DNX-2401): DNAtrix
-
ONC201: Chimerix
-
Selinexor (KPT-330): Karyopharm Therapeutics
-
Paxalisib (GDC-0084): Kazia Therapeutics
-
AV-Glioblastoma Multiforme-1: Aivita Biomedical
-
MDNA55: Medicenna Therapeutics
-
Avastin: Genentech
-
Temodar/Temodal: Merck
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Glioblastoma Multiforme Competitive Intelligence Analysis
4. Glioblastoma Multiforme Market Overview at a Glance
5. Glioblastoma Multiforme Disease Background and Overview
6. Glioblastoma Multiforme Patient Journey
7. Glioblastoma Multiforme Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Glioblastoma Multiforme Treatment Algorithm, Current Treatment, and Medical Practices
9. Glioblastoma Multiforme Unmet Needs
10. Key Endpoints of Glioblastoma Multiforme Treatment
11. Glioblastoma Multiforme Marketed Therapies
12. Glioblastoma Multiforme Emerging Drugs and Latest Therapeutic Advances
13. Glioblastoma Multiforme Seven Major Market Analysis
14. Attribute Analysis
15. Glioblastoma Multiforme Market Outlook (In US, EU5, and Japan)
16. Glioblastoma Multiforme Companies Active in the Market
17. Glioblastoma Multiforme Access and Reimbursement Overview
18. KOL Views on the Glioblastoma Multiforme Market
19. Glioblastoma Multiforme Market Drivers
20. Glioblastoma Multiforme Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Acute Lymphocytic Leukemia (ALL) Market
“Acute Lymphocytic Leukemia (ALL) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Lymphocytic Leukemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute Lymphocytic Leukemia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/